Myeloid cells are a major component of tumour‐infiltrating cells in TME, contributing to resistance during immunotherapy by increasing the expression of signal regulatory protein‐alpha (SIRPα) and suppressing antitumoral abilities of T and natural killer (NK) cells in TME.6, 8. This evidence concerns the gene SIRPA and neoplasm.